Catabasis

$6.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.50%) Today
+$0.01 (0.17%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Catabasis and other stocks, options, ETFs, and crypto commission-free!

About CATB

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. Read More The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
70.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
30.99K
High Today
$6.19
Low Today
$5.90
Open Price
$6.06
Volume
29.06K
52 Week High
$9.76
52 Week Low
$3.60

Collections

CATB Earnings

-$0.90
-$0.63
-$0.35
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.